CLIC6 mRNA was downregulated in PRAD and BRCA, indicating that low CLIC6 expression is associated with higher TMB, MSI, and NEO scores in PRAD and BRCA patients, suggesting that PRAD and BRCA patients with lower CLIC6 expression may benefit more from immunotherapy. Here, CLIC6 is linked to prostate adenocarcinoma.